Inulin

Inulin

1. Identity: Chemical Name, Botanical Sources, and Common Forms

Chemical Identity

Inulin is a naturally occurring, water-soluble, storage polysaccharide that belongs to a group of non-digestible carbohydrates called fructans. Chemically, it is composed of fructosyl units linked by β-(2→1) glycosidic bonds, with a terminal glucose moiety attached via an α-(1→2) linkage. Inulin is known to have linear chains incorporating 2–60 fructose units linked by β-(2,1)-fructosyl-fructose bonds, with chain length and polydispersity depending on the plant species, maturity degree, and extraction process used.

Inulin is the second most abundant carbohydrate storage in plants and is distributed across various parts such as bulbs, roots, root tubers, leaf bases, grains, and fruits. Inulin is a natural storage carbohydrate present in more than 36,000 species of plants, including agave, wheat, onion, bananas, garlic, asparagus, Jerusalem artichoke, and chicory. For these plants, inulin is used as an energy reserve and for regulating cold resistance.

Because inulin has β(2→1) linkages, it reaches the colon intact, without enzymatic hydrolysis in the upper gastrointestinal tract. This structural feature is the fundamental basis of inulin's prebiotic activity and its classification as a dietary fiber.

Nomenclature and Related Compounds

The term "inulin" derives from the genus Inula, particularly Inula helenium (elecampane). Inulin-type fructans (ITF) include short-chain fructooligosaccharides (scFOS), oligofructose, and inulin, all of which are commonly used fibers widely regarded as prebiotic for their ability to be selectively utilized by the intestinal microbiota to confer a health benefit. Commercially produced fructooligosaccharides (FOS) are obtained by extraction and hydrolysis of the inulin molecule present in many plants and by enzymatic transfructosylation of the sucrose molecule. Inulin is a fructose polymer, or polyfructose, with a degree of polymerization of from 10 to 60.

Principal Botanical Sources

Inulin serves as a storage polymer in many plants of the Asteraceae (formerly Compositae) family such as globe artichoke (Cynara cardunculus L.), chicory (Cichorium intybus L.), Jerusalem artichoke (Helianthus tuberosus L.), and elecampane (Inula helenium). Dicotyledonous plants such as the Asteraceae and Campanulaceae families are rich sources of inulin. Nutritional inulin-containing plants include leek, onion, garlic, asparagus, Jerusalem artichoke, dahlia, chicory, and yacon.

Chicory root is the main source of extraction for commercial production of inulin. The extraction process for inulin is similar to obtaining sugar from sugar beets. After harvest, the chicory roots are sliced and washed, then soaked in a solvent (hot water or ethanol); the inulin is then isolated, purified, and spray dried. Besides chicory, other plants from which inulin is extracted are Jerusalem artichoke (Helianthus tuberosus) and blue agave (Agave tequilana).

Jerusalem artichoke tubers can contain up to 16–20% inulin by fresh weight, with some cultivars reaching even higher concentrations. The inulin content varies seasonally, with peak levels occurring after the first frost when starches convert to inulin. Chicory inulin typically has a degree of polymerization (DP) ranging from 2 to 60, with an average DP of 10–12.

Common Dosage Forms and Preparations

Inulin is commercially available in several forms:

• Powder/granules: The most common supplement form, typically derived from chicory root, presented as a fine white to off-white powder that dissolves in liquids.
• Food-additive form: Inulin is widely utilized in the food industry as a functional ingredient to replace sugar and fat, enhancing nutritional profiles while reducing caloric content.
• Oligofructose/FOS preparations: Shorter-chain hydrolysis products of inulin, often sold separately or blended with native inulin.
• Synbiotic formulations: Combined with probiotic bacteria in capsule or powder form.
• Enriched foods: GRAS determinations permit inulin's use across a broad range of food categories including baked goods, dairy products, beverages, nutrition bars, and dietary supplements.

2. Historical and Traditional Use

Ancient Use of Inulin-Rich Plants

Pedanios Dioscoride, a physician with the Roman army, in 100 AD reported the beneficial effects of chicory root extract (approximately 40% inulin by weight) for treatment of stomach, liver, and kidney complaints. Common chicory (Cichorium intybus) is a somewhat woody, perennial herbaceous plant of the family Asteraceae, usually with bright blue flowers, native to Europe, North Africa, and western Asia.

The Jerusalem artichoke has been used globally throughout history as a dietary supplement, for pain treatment, to reduce swelling, and to boost the immune system, as well as to treat skin wounds in folk medicine. Helianthus tuberosus (Jerusalem artichoke), is an inulin-containing dicotyledonous species related to the common sunflower, native to the eastern US. The Jerusalem artichoke's historical use in the diet as an adequate potato substitute has caused it to be referred to as "wild potato," "horse potato," and "diabetic potato," the last owing to its storage of a non-digestible carbohydrate that does not induce any significant glycemic response, as compared with the glycemia-inducing starch in potato.

The tubers were also cultivated extensively after World War II in France and Germany and other areas when potatoes were scarce as a result of famine. Based on values of inulin content ranging from 16 to 20 percent, approximately 25 to 32 grams per day of inulin was consumed by these populations.

The roots of scorzonera and salsify are used as vegetables, while dried and roasted roots of dandelion and chicory are used as coffee substitutes and in medicine. The use of chicory root as a coffee substitute became especially prominent in Europe during periods of coffee shortage, including during both World Wars.

Scientific Isolation and Naming

In 1804, German pharmacologist Valentin Rose the Younger isolated inulin for the first time from the roots of Inula helenium (elecampane) through boiling-water extraction, describing it as a peculiar white, crystalline substance distinct from known carbohydrates like starch. This discovery represented the initial identification of inulin as a plant-derived polysaccharide, sparking interest in its chemical properties and potential applications.

The substance was named "inulin" in 1817 by Scottish chemist Thomas Thomson, who provided the first detailed description of its physicochemical characteristics, including its solubility in hot water and its ability to form spherocrystals upon cooling. Subsequent early 19th-century research focused on its extraction from elecampane and other sources, with systematic studies in the 1840s advancing purification techniques and confirming its presence in related plants.

Oral inulin's beneficial effects on metabolic disorders were re-discovered in 1874, with a report that diabetic patients lost their glycosuria when put on a diet of 100 g of inulin per day. In the 1920s, J. Irvine used chemical methods such as methylation to study the molecular structure of inulin, and he designed the isolation method for a new anhydrofructose.

By the late nineteenth century, chemists had identified chicory root as one of the richest natural sources, and European farmers began cultivating chicory specifically for its root rather than its leaves. The modern chapter of inulin's history started in the 1990s, when advances in extraction technology made it practical to produce a high-purity, neutral-tasting powder at commercial scale.

3. Key Constituents and Mechanisms of Action

Structural Properties and Non-Digestibility

Inulin belongs to a class of carbohydrates called fructans — chains of fructose molecules linked together with a terminal glucose unit at one end. The bonds between these fructose units are beta-(2→1) glycosidic linkages. Human digestive enzymes cannot break these bonds, meaning inulin passes through the stomach and small intestine largely intact. As a result, inulin does not alter blood glucose levels nor interfere with the insulin–glucagon counter-balance.

Colonic Fermentation and Short-Chain Fatty Acid Production

Inulin, consisting of repetitive fructosyl units linked by β(2,1) bonds, is a readily fermentable fiber by intestinal bacteria that generates large quantities of short-chain fatty acids (SCFAs). It is hydrolyzed by β-fructosidase-producing bacteria and increases the Bifidobacteria population (bifidogenic effect) in the colon.

Inulin's efficacy is mainly attributed to mechanisms such as the modulation of gut microbiota composition, plasma metabolome (e.g., SCFAs, bile acids, and amino acids), and reduction of systemic inflammation. The sugar chain of inulin is longer compared with that of oligofructose, resulting in slower fermentation and gas production. This slower fermentation profile means long-chain inulin tends to be fermented more distally in the colon than shorter-chain FOS.

SCFAs and Downstream Signaling

One major function of the gut microbiota is the metabolism of non-digestible carbohydrates (NDC), which leads to the production of SCFAs as the major end-products. SCFAs have been shown to have a range of beneficial effects, including improved immune function, adiposity, and glucose regulation, albeit the data come almost exclusively from animal models.

These metabolites can enter the circulation and regulate the release of anti-inflammatory factors (e.g., interleukin-10 (IL-10)) by immune cells, depending on the inflammatory microenvironment. Inulin also promotes homeostatic remodeling of colonic epithelium through the γδT cell–IL-22 axis via regulating gut microbiota and its metabolites.

Appetite-Regulatory Hormones

Research has demonstrated that inulin-type fructans (ITF) have the potential to induce satiety through enhanced secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), as well as reduced secretion of orexigenic hormone acyl-ghrelin. The release of GLP-1 and PYY from enteroendocrine L-cells in the distal gut can induce satiety through activation of appetite-suppressing regions within the arcuate nucleus of the hypothalamus.

Lipid Metabolism

The mechanism for improving the lipid profile may be attributed to the increase in muscle lipoprotein lipase enzyme activity, which promotes the production of SCFAs. Moreover, the increased production of the SCFA acetate and propionate are implicated in lipid-lowering effects.

4. Scientific Evidence by Area of Use

4.1 Gut Microbiota Modulation (Prebiotic Effect)

The prebiotic effect of inulin is the most robustly documented area of evidence in human studies. Inulin-type fructans, including short-chain fructooligosaccharides (scFOS), oligofructose, and inulin, are commonly used fibers that are widely regarded as prebiotic for their ability to be selectively utilized by the intestinal microbiota to confer a health benefit.

A 2021 systematic review in Advances in Nutrition is among the most comprehensive assessments of human evidence. Overall, 78 publications were included. Of these, 45 reported results on the fecal microbiota and related metabolites (e.g., SCFAs, bile acids). Thirty-six publications included results on gastrointestinal physiology, including intestinal permeability, transit time, and tolerance. Eighteen publications included results on cardiovascular health, 15 on glucose homeostasis, 10 on mineral absorption and bone health, 13 on appetite and satiety, 10 on body composition and energy balance, and 5 on inflammation. To ensure that interventions were of sufficient duration to capture the changes occurring in the gastrointestinal tract, 1 week was used as the minimum duration, though studies ranged up to 24 months. Doses ranged from 2.5 to 50 g/d.

Beneficial health effects reported following ITF intake include improved intestinal barrier function, improved laxation, increased insulin sensitivity, decreased triglycerides and an improved lipid profile, increased absorption of calcium and magnesium, and increased satiety. Although there is some evidence for differing effects of ITF based on chain length, the lack of direct comparisons and detailed descriptions of physicochemical properties limits the ability to draw conclusions from human clinical studies.

A 2019 systematic review in the European Journal of Clinical Microbiology and Infectious Diseases specifically examined human studies on the effects of inulin on the gut microbiome. In individuals with constipation, it was reported that inulin ingestion was associated with a significant increase in stool frequency, suggesting a potential impact of inulin on human gut microbiota composition.

A clinical intervention study in healthy women examined three dietary fiber supplements (inulin, Vitafiber, and Fibremax), each consumed for one week with a two-week washout period. The researchers found that overall both the gut microbiota and immune response remained stable, but each fiber produced its own specific alterations in terms of microbiota diversity and SCFA production. Inulin was the only fiber that resulted in significant and reproducible effects on SCFA production and immune cell phenotypes, with specific microbial taxa emerging as possible biomarkers.

Evidence strength: The bifidogenic effect (selective increase in Bifidobacterium species) is among the best-supported effects of inulin in humans, backed by multiple RCTs and mechanistic data. Broader claims regarding full microbiome remodeling require more rigorous investigation due to interindividual variability.

4.2 Glucose Homeostasis and Type 2 Diabetes

A 2021 prospective single-arm study conducted at Peking Union Medical College Hospital enrolled prediabetic subjects to assess inulin's effects on glucose metabolism. A total of 49 subjects with prediabetes (WHO 1999 criteria) were voluntarily enrolled, and each subject received a daily supplement of 15 g of inulin for 6 months. After 24 weeks of intervention, inulin significantly decreased fasting insulin and 2-hour post-OGTT insulin and improved HOMA-IR. Limitations include the lack of a parallel placebo control group.

A 2020 meta-analysis in PMC (Efficacy of inulin supplementation in improving insulin control, HbA1c and HOMA-IR in patients with type 2 diabetes) focused on RCTs in type 2 diabetes patients. Inulin, a kind of water-soluble storage polysaccharide and non-digestible carbohydrate and a type of fructan, has in recent years been widely applied as a dietary supplement to improve blood glucose and lipids. The mechanism of inulin on glucose and lipids is still under discussion compared with other fibers such as β-glucan, which improves insulin resistance by regulating multiple receptors and activating the PI3K/Akt signaling pathway.

A 2015 randomized controlled trial investigated inulin's effect on weight management and ectopic fat in prediabetes. Forty-four subjects with prediabetes were randomized to 18 weeks' inulin or cellulose supplementation. During weeks 1–9 (weight loss phase), all subjects had four visits with a dietitian to guide them towards a 5% weight loss. Inulin may have a two-pronged effect on the risk of diabetes by promoting weight loss and reducing intrahepatocellular and intramyocellular lipid in people with prediabetes independent of weight loss.

Evidence strength: Moderate. Multiple RCTs and meta-analyses show improvements in fasting glucose, insulin sensitivity, and HbA1c in patients with type 2 diabetes or prediabetes, but study populations, doses, and durations are heterogeneous. Effects appear most consistent for improving insulin sensitivity rather than fasting glucose alone.

4.3 Lipid Profile and Cardiovascular Health

A positive correlation between baseline triglyceride concentration and decreases in triglycerides following inulin consumption has been observed — that is, higher baseline triglycerides are associated with a greater decrease. A systematic review further concluded that, although the results vary across studies, inulin-type carbohydrates may have a positive effect on blood pressure.

Mechanistically, inulin-mediated fermentation leads to the production of SCFAs, which influence immune cell activity and metabolic signaling. Experimental evidence also suggests that inulin affects the expression of genes involved in vascular function and can counteract the hypertensive effects of high fructose intake.

Evidence strength: Preliminary to moderate. Evidence for triglyceride reduction is more consistent than for LDL-cholesterol or total cholesterol. Blood pressure effects are heterogeneous across studies. Much of the mechanistic evidence is from animal or in vitro models.

4.4 Bowel Function and Gastrointestinal Health

Experimental studies have shown that inulin supplementation alleviates ulcerative colitis symptoms by reducing proinflammatory cytokine expression and improving histopathological features of the intestinal mucosa, thereby facilitating tissue recovery. Beyond its microbiota-regulating function, inulin also relieves constipation and enhances mineral absorption, supporting intestinal motility and mucosal integrity.

The European Food Safety Authority (EFSA) has authorized an "improvement of bowel function" health claim for native chicory inulin at 12 g/day in the EU. This represents one of the strongest regulatory-level endorsements of a specific health effect for inulin, based on reviewed clinical evidence.

Regarding inflammatory bowel disease (IBD), preclinical data are promising. Inulin digesta significantly reduced pro-inflammatory cytokine expression (CXCL8/IL8 and TNFα) and increased MUC2 expression in intestinal epithelial cells. In vivo, inulin intake significantly prevented IBD symptoms, substantiated by a decrease in serum inflammatory markers (IL-6, CALP) and downregulation of inflammatory cytokines in colon samples. However, this evidence is largely from animal models. Inulin can cause serious side effects in patients with inflammatory bowel disease (IBD) or allergies, and caution is warranted in active IBD flares.

Evidence strength: Strong for laxation and stool frequency improvement (EFSA-authorized claim). Preliminary for IBD management — primarily based on preclinical and small human trials.

4.5 Mineral Absorption and Bone Health

ITF may also impact mineral absorption. Animal studies consistently report a positive effect of ITF on mineral absorption, particularly calcium and magnesium, and bone mineral density.

Human evidence for calcium absorption was demonstrated in a study by Coudray et al. (1997): Nine healthy young men (mean age 22 years) were given a controlled diet (859 ± 196 mg/day of calcium) with or without 40 g/day of inulin extracted from chicory root in a 28-day randomized crossover design study. The inulin diet consisted of two days of the control diet, followed by 14 days of progressive increase in inulin consumption, and then 12 days of constant inulin consumption.

A longer-term study in adolescents found that: after adjusting for multiple covariates (sex, ethnicity, Tanner stage of puberty, and Fok1 genotype for vitamin D receptor), change in whole-body bone mineral content and bone mineral density were significantly greater in the inulin + oligofructose group compared to the control group.

Evidence strength: Moderate, primarily from shorter-term calcium absorption studies in healthy adults and adolescents. The mechanism (enhanced colonic fermentation lowering luminal pH and increasing calcium solubility) is biologically plausible and supported across multiple human studies, though long-term fracture or bone density data remain limited.

4.6 Body Weight, Appetite, and Satiety

When participants consumed 16 g/day of ITFs in the morning, the average ratings in their "desire to eat," "hunger," and "prospective food consumption" were significantly lower compared to the control group. In addition, the fiber group reported higher "fullness" ratings just before lunch, suggesting a potential impact from the fiber.

In an 18-week RCT in prediabetic subjects, the inulin group maintained superior weight loss during the maintenance phase: Both groups lost approximately 5% of their body weight by week nine (−5.3 ± 0.1% vs −4.3 ± 0.4%, p = 0.13), but the inulin group lost significantly more weight between 9 and 18 weeks (−2.3 ± 0.5% vs −0.6 ± 0.4%, p = 0.012).

Researchers showed that glucagon-like peptide (GLP)-1 and GLP-2 contents increased in the proximal colon by ITF fermentation. This suggests that ITF can modulate endogenous production of gut peptides involved in appetite, concentration of ghrelin, and body weight regulation, leading to decreased food intake.

Evidence strength: Moderate for acute appetite suppression in single-meal studies; evidence for sustained weight loss is preliminary and inconsistent across trials. Effect sizes tend to be modest, and long-term maintenance of weight effects has not been conclusively demonstrated in large RCTs.

4.7 Immune Function and Inflammation

Inulin can regulate the metabolism of glucose, lipids, and amino acids, in addition to intestinal immune and systemic immunomodulatory effects. Its intestinal metabolites also exert beneficial functions. An inulin-rich diet has been reported to improve the function of the intestinal barrier and modulate the immune system.

One randomized trial noted that inulin supplementation at 16 g/day resulted in doubling of Faecalibacterium prausnitzii and other SCFA producers, with concurrent decreases in serum CRP and LPS concentration.

Evidence strength: Preliminary. While mechanistic plausibility is supported and some biomarker data are encouraging, robust long-term RCTs directly measuring clinical immune outcomes (e.g., infection rate, autoimmune disease activity) remain limited.

4.8 Chronic Kidney Disease (CKD)

A longitudinal prospective controlled study evaluated inulin's effects in CKD patients. The study evaluated the effects of a low-protein diet (0.6 g/kg/day) with or without the intake of the prebiotic inulin (19 g/day) on microbiota and clinical parameters in CKD patients, involving 16 patients total. The study found a significant reduction, only after treatment with inulin, in terms of TNF-α and NOX2 levels.

A pilot crossover RCT in hemodialysis patients used inulin at 10 g/d for females and 15 g/d for males, or maltodextrin as control, for 4 weeks, with a 4-week washout period. Inulin increased the relative abundance of the phylum Verrucomicrobia and its genus Akkermansia.

Evidence strength: Preliminary. Studies are small and exploratory. Inulin's ability to modulate gut microbiota and reduce uremic toxin precursors is biologically plausible, but larger RCTs are needed before clinical recommendations can be made.

4.9 Colorectal Cancer (Preclinical)

A 2025 systematic review and meta-analysis evaluated inulin's effects on colorectal cancer (CRC) risk. A comprehensive search of nine databases led to the selection of 12 studies from an initial pool of 114 articles. Meta-analyses showed that inulin supplementation significantly reduced aberrant crypt foci count in rats, increased cecal weight, enhanced colonic Lactobacillus counts, decreased coliform bacteria, and elevated colonic SCFA levels.

Evidence from human studies remains limited, highlighting the need for systematic reviews and meta-analyses of experimental research. Long-term dose–response studies are necessary to determine the "therapeutic window" for inulin intervention, while attention should also be given to how interindividual variations in microbial metabolism might influence treatment outcomes. It is recommended to further investigate the specific inhibitory effects of inulin metabolites on cancer stem cells using organoid models and to support the translation of preclinical findings into phase I clinical trials.

Evidence strength: Preclinical only (animal models). No human clinical trial evidence is available to support a cancer-preventive indication at this time.

5. Body Systems and Health Areas

Inulin can improve the symptoms of many diseases, such as metabolic syndrome, IBD, and chronic kidney disease (CKD), associated with intestinal inflammation and intestinal dysbiosis, as well as allergic diseases and tumors related to immune imbalance. The primary body systems with documented associations include:

• Gastrointestinal system: Microbiota composition, intestinal barrier integrity, bowel transit, constipation relief, and IBD-related inflammation.
• Metabolic system: Dietary supplementation with inulin has been demonstrated to show significant potential benefits for the management of metabolic disorders, including insulin resistance, type 2 diabetes mellitus, and cardiometabolic diseases.
• Cardiovascular system: Triglyceride reduction, lipid profile improvement, and potential blood pressure modulation.
• Musculoskeletal system: Enhanced calcium and magnesium absorption with implications for bone mineral density.
• Neuroendocrine/appetite regulation: GLP-1 and PYY secretion modulation affecting satiety and food intake.
• Immune system: Modulation of intestinal immune cells, SCFA-mediated anti-inflammatory signaling, and cytokine regulation.
• Renal system: Emerging evidence for CKD-related microbiota and inflammatory marker modification.

6. Dosage Forms and Reported Study Dosages

The following dosages have been specifically reported in identified research:

• 15 g/day for 6 months in a prediabetes gut microbiota and insulin sensitivity study.
• 40 g/day of chicory root inulin in a 28-day randomized crossover study assessing calcium absorption in healthy young men.
• Study durations in the systematic review of 78 publications ranged from 1 week to 24 months. Doses ranged from 2.5 to 50 g/d.
• 10 g/d for females; 15 g/d for males in a randomized, double-blind, placebo-controlled crossover study in hemodialysis patients for 4 weeks.
• 16 g/day of ITFs used in an appetite/satiety study demonstrating reduced hunger and desire to eat.
• 20 g of oligofructose-enriched inulin in a randomized crossover satiety study following exercise.
• 19 g/day used in combination with a low-protein diet in a CKD intervention study.
• 16 g/day in a randomized trial demonstrating doubling of F. prausnitzii and concurrent decreases in CRP and LPS.
• EFSA's authorized health claim for bowel function specifies 12 g/day of native chicory inulin.
• No serious adverse events have been reported in trials using doses up to 34 g/day inulin or 55 g/day mixed fiber, with self-resolving bloating as the main side effect.

7. Safety, Tolerability, and Notable Interactions

Regulatory Status

In the United States, inulin derived from chicory root has been affirmed as Generally Recognized As Safe (GRAS) by the FDA since 2005 (GRN 000118), with additional GRAS notifications covering long-chain inulin (GRN 000392) and short-chain fructooligosaccharides (GRN 000044). In the European Union, the European Food Safety Authority (EFSA) has evaluated inulin-type fructans and approved specific health claims. Notably, EFSA concluded that a daily intake of 12 g of chicory inulin "contributes to normal bowel function by increasing stool frequency." Chicory-derived inulin has GRAS status in the USA since 2003 for use in a variety of food applications and is authorised to be used in all unstandardised foods in Canada.

Gastrointestinal Tolerability

At doses up to 20 g/day for up to 12 months, inulin appears to be generally well-tolerated. The primary adverse effects observed are mild and transient gastrointestinal symptoms, which are common with non-digestible fibres. Inulin can cause some side effects, such as nausea, bloating, flatulence, itching, and heartburn.

No ADI (Acceptable Daily Intake) or human tolerance level is formally set for inulin. Although inulin is regarded as without serious adverse effects at high levels (up to 20 g/day), there is a wide interpersonal variability in the doses at which gastrointestinal effects associated with colonic fermentation will appear.

Studies lasting 6 to 12 weeks at doses of 10 to 16 grams per day report only mild side effects: bloating, flatulence, soft stools, and occasional rumbling or cramping.

FODMAP and IBS Concerns

Since inulin is a fructan with a high FODMAP profile, symptoms are significantly amplified in individuals with IBS or SIBO sensitivity. For individuals following a low-FODMAP diet for IBS management, inulin represents a documented high-FODMAP ingredient that may worsen gastrointestinal symptoms. Longer-chain inulin reaches more distal regions of the colon before fermentation begins, which can result in different symptom patterns — often more bloating and less immediate flatulence compared to rapidly fermenting oligosaccharides.

Allergy and Compositae Sensitivity

Inulin can cause serious side effects in patients with inflammatory bowel disease (IBD) or allergies. Individuals with documented hypersensitivity to plants in the Asteraceae/Compositae family (e.g., chicory, dandelion, ragweed, chrysanthemums) may be at risk of allergic reactions to chicory-derived inulin preparations, as cross-reactivity has been noted in the literature.

Absence of Known Drug Interactions

No clinically significant pharmacokinetic drug interactions have been established for inulin in the peer-reviewed literature reviewed. Although inulin has been approved by the FDA (in the USA) and by EFSA (in Europe) and is considered a GRAS ingredient, no ADI (Advised Daily Intake) limits have been officially set. The primary safety signals identified in clinical trials remain dose-dependent gastrointestinal symptoms rather than systemic toxicity.

Special Populations

Inulin may improve the symptoms of many diseases, such as metabolic syndrome, IBD, and chronic kidney disease, associated with intestinal inflammation and intestinal dysbiosis. However, active, severe IBD flares represent a condition where increased fiber fermentation could theoretically exacerbate symptoms, and the available evidence in these populations is insufficient to guide therapeutic dosing without clinical monitoring.

References

• Wang X et al. Dietary Supplementation with Inulin Modulates the Gut Microbiota and Improves Insulin Sensitivity in Prediabetes. J Diabetes Res. 2021. PMC8261184.
• Madsen MSA et al. The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review. Advances in Nutrition. 2022.
• The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review. PubMed PMID 34555168.
• Inulin as a Biopolymer; Chemical Structure, Anticancer Effects, Nutraceutical Potential and Industrial Applications: A Comprehensive Review. PMC11819723.
• Immunomodulatory effects of inulin and its intestinal metabolites. Frontiers in Immunology. 2023. PMC10449545.
• Frontiers in Immunology: Immunomodulatory effects of inulin and its intestinal metabolites. 2023.
• Efficacy of inulin supplementation in improving insulin control, HbA1c and HOMA-IR in patients with type 2 diabetes: a systematic review and meta-analysis. PMC7263925.
• A randomized controlled trial: the effect of inulin on weight management and ectopic fat in subjects with prediabetes. PMC4619305.
• Randomised clinical study: inulin short-chain fatty acid esters for targeted delivery of SCFAs to the human colon. PMC5026196.
• Acute fiber supplementation with inulin-type fructans curbs appetite sensations: a randomized, double-blind, placebo-controlled study. PMC5510210.
• Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study. PMC8403151.
• Effect of Low-Protein Diet and Inulin on Microbiota and Clinical Parameters in Patients with Chronic Kidney Disease. PMC6950025.
• Protective Effects of Inulin on Stress-Recurrent Inflammatory Bowel Disease. PMC10931620.
• Oligofructose-Enriched Inulin Consumption Acutely Modifies Markers of Postexercise Appetite. PMC10745446.
• Effects of inulin supplementation on body composition and metabolic outcomes in children with obesity. PMC9338247.
• The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review. Advances in Nutrition. ScienceDirect.
• Inulin extraction from common inulin-containing plant sources. Industrial Crops and Products. ScienceDirect.
• Inulin — an overview. ScienceDirect Topics.
• The effects of inulin on gut microbial composition: a systematic review of evidence from human studies. European Journal of Clinical Microbiology & Infectious Diseases. 2019.
• Safety of inulin-propionate ester as a novel food. EFSA Journal. 2025.
• VKM Report 2016:01 Risk assessment of "other substances" – Inulin. Norwegian Scientific Committee for Food Safety.
• FDA Review of the Scientific Evidence on the Physiological Effects of Certain Non-Digestible Carbohydrates. U.S. Food and Drug Administration.
• Inulin as a multifunctional prebiotic: from gut modulation to systemic health benefits. Food Quality and Safety. Oxford Academic.
• Inulin Modulates Gut Microbiota and Increases Short-Chain Fatty Acids Levels to Inhibit Colon Tumorigenesis in Rat Models: A Systematic Review and Meta-Analysis. Journal of Food Science. 2025.
• Dietary fiber inulin mitigates peripheral neuropathy in different stages of diabetes via modulating gut microbiota and metabolites in db/db mice. PMC12633925.
• Exploring the Therapeutic Potential, Ethnomedicinal Values, and Phytochemistry of Helianthus tuberosus L.: A Review. PMC11676200.
• Ultrasound-assisted extraction, quantification and characterization of inulin from agave, chicory and Jerusalem artichoke. Scientific Reports. 2026.
• Inulin. Wikipedia.
• Inulin as a Biopolymer; Chemical Structure, Anticancer Effects, Nutraceutical Potential and Industrial Applications. Polymers. MDPI. 2025.
• Prebiotic Type Spotlight: Inulin. Global Prebiotic Association. 2025.
• Inulin for Infections in the Intensive Care Unit — Protocol/SAP. ClinicalTrials.gov NCT03865706.